Metformin
Metformin
METFORMIN
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.17 (-1.71 to 0.13) | 0.45 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.75 (-1.42 to 0.30) | 0.42 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -5.02 (-10.60 to 2.91) | 0.86 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -5.64 (-10.93 to 1.07) | 0.89 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Dulaglutide 0.75 mg subcutaneous once weekly | MD -1.07 (-5.72 to 3.76) | 0.69 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Dulaglutide injection | MD -0.69 (-5.73 to 4.44) | 0.69 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.27 (-2.33 to 1.72) | 0.51 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.20 (-3.88 to 4.12) | 0.45 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.11 (0.00 to 2.58) | 0.69 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.08 (0.00 to 1.89) | 0.69 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.58 (0.02 to 15.90) | 0.74 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.79 (0.24 to 2.39) | 0.69 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.89 (0.27 to 2.63) | 0.73 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.71 (0.13 to 3.22) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.55 (0.10 to 2.83) | 0.66 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.10 (-1.80 to 1.72) | 0.23 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 0.55 (-1.50 to 2.71) | 0.22 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 4.53 (-1.10 to 10.17) | 0.33 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 1.56 (-4.04 to 8.82) | 0.37 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.80 (0.42 to 1.47) | 0.60 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.76 (0.39 to 1.44) | 0.67 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.39 (0.41 to 4.30) | 0.55 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.29 (0.42 to 3.89) | 0.52 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.35 (1.33 to 4.13) | 0.55 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.85 (1.33 to 6.31) | 0.36 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.07 (0.57 to 1.90) | 0.74 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.26 (0.59 to 2.62) | 0.61 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.89 (1.29 to 2.79) | 0.42 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.98 (1.28 to 3.03) | 0.33 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.46 (0.21 to 0.90) | 0.83 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.52 (0.24 to 1.07) | 0.75 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.71 (0.01 to 47.85) | 0.61 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.74 (0.01 to 55.28) | 0.55 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.54 (0.04 to 6.25) | 0.57 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.48 (0.04 to 5.71) | 0.52 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.44 (0.00 to 32.72) | 0.64 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.42 (0.00 to 33.77) | 0.68 |
| Children and adolescents with type 2 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Standard care or no added treatment | MD 0.52 (-1.29 to 2.30) | 0.32 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Placebo | HR 0.52 (0.08 to 2.89) | 0.92 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Placebo | HR 2.80 (0.81 to 8.22) | 0.51 |
| Polycystic ovary syndrome | Vomiting | longest follow-up | Placebo | HR 6.36 (0.79 to 54.36) | 0.31 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Placebo | HR 0.95 (0.11 to 7.35) | 0.76 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Placebo | HR 1.83 (0.41 to 8.75) | 0.50 |
Trials
- S0034372025 · 180 randomized · 24 weeks
- NCT06896981Comparison Between the Effects of Low-Dose Semaglutide With Metformin vs. Metformin Alone Over Metabolic Profile in Obese Polycystic Ovary Syndrome: A Phase II Randomized Controlled Trial2025 · 31 randomized · 16 weeks
- S0034362023 · 150 randomized · 24 weeks
- S0029512022 · 156 randomized · 16 weeks
- S0030502020 · 60 randomized · 12 weeks
- S0030222018 · 60 randomized · 12 weeks
- NCT03010683Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus2015 · 60 randomized · 26.07 weeks
- NCT03068065Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD)2014 · 93 randomized · 24 weeks
- NCT02187250Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome2014 · 45 randomized · 12 weeks
- RISE AdultRestoring Insulin Secretion Adult Medication Study2013 · 267 randomized · 52.14 weeks
- S0031082012 · 24 weeks
- NCT01911468Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin2011 · 40 randomized · 12 weeks
- NCT01126580The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)2010 · 807 randomized · 52 weeks
- NCT00676338Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes2008 · 820 randomized · 26 weeks
- NCT00546728The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance2007 · 50 randomized · 13.04 weeks